Lenzing Biocel Paskov's net debt stood at CZK -1,587 mil and accounted for -25.2% of equity at the end of 2019. The ratio is down 6.88 pp compared to the previous year.
Historically, the firm’s net debt to equity reached a high of 105% in 2013 and a low of -25.4% in 2017 between 2007 and 2019. The average for the last five years was -11.7%.
Net debt to EBITDA was calculated at -0.819x at the end of the year. That is down from 1.65x seen in 2014. The ratio reached a high of 7.35x in 2012 and a low of -0.819x in 2019.
The company’s cost of funding amounted to in 2019, down which is above the 5-year of 3.62%. Funding costs have “eaten” some 0% of the operating profit generated in 2019.
You can see all the company’s data at Lenzing Biocel Paskov profile, or you can download a report on the company in the report section.
Helgi Library 
